Rhenman & Partners Asset Management

Hedge Fund Stockholm, Sweden ·Founded 2008

Overview

Rhenman & Partners Asset Management is a Stockholm-based hedge fund specializing in healthcare investments. The firm manages a sector-specific hedge fund registered in Luxembourg, focusing on the healthcare sector. The investment team is supported by a scientific advisory board consisting of medical experts with a global network of researchers and specialists. The firm was founded in 2008 and is based in Stockholm, Sweden. The hedge fund has assets under management of approximately $615 million. The firm focuses on long/short strategies. The firm's headquarters are located at Strandvägen 5a, Stockholm 11451, Sweden. The main fund email is [email protected]. The firm's leadership includes Carl Grevelius (Founder), Henrik Rhenman (Chief Investment Officer), Goran Nordstrom (CEO), and Susanna Urdmark (Portfolio Manager).

Portfolio Companies

AstraZenecaOncoOneOrionSobiSwedish Orphan BiovitrumHansa BiopharmaSCAMedivirOasmia PharmaceuticalGetingeMedicoverBiocrineElektaMedaRecipharm

Reach Rhenman & Partners Asset Management directly

Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.

Unlock full contacts →

Frequently asked questions about Rhenman & Partners Asset Management

What sectors does Rhenman & Partners Asset Management invest in?

Rhenman & Partners Asset Management invests in Healthcare, Healthcare Services, Pharmaceuticals, Medical Devices, Diagnostics and Biotechnology, and is based in Stockholm, Sweden. Rhenman & Partners Asset Management is listed as a hedge fund in the ConnectSafely investor database.

What stage does Rhenman & Partners Asset Management invest at?

Rhenman & Partners Asset Management backs companies at Growth, Late Stage and Pre-IPO, writing cheques of 10M - 50M.

Which regions does Rhenman & Partners Asset Management invest in?

Rhenman & Partners Asset Management invests across Luxembourg and Sweden.

What companies has Rhenman & Partners Asset Management invested in?

Rhenman & Partners Asset Management's portfolio includes AstraZeneca, OncoOne, Orion, Sobi, Swedish Orphan Biovitrum, Hansa Biopharma, SCA and Medivir.

Last updated · Source: ConnectSafely investor database